DexCom Incorporated – Patent Portfolio Analysis

Ownership and Acquisition 

• Acquired Patents: 74 

• Originally Assigned Patents: 3,660 

Sources of Acquired Patents: 

• Operating Company: 58 

• University: 3 

• Other: 10 

 Citations 

Top Citing Assignees (Forward Citations) 

• DexCom Incorporated – 997 

• Abbott Laboratories – 415 

• GlucoTrack, Inc. – 295 

• Medtronic Plc – 227 

• Biolinq Incorporated – 195 

• Roche Holding AG – 155 

• Samsung Electronics Co. Ltd. – 99 

• University of Virginia – 99 

• ICU Medical Incorporated – 96 

• Senseonics Holdings, Inc. – 84 

Top Cited Assignees (Backward Citations) 

• DexCom Incorporated – 1,710 

• Abbott Laboratories – 1,330 

• Medtronic Plc – 1,328 

• Roche Holding AG – 1,081 

• Platinum Equity Advisors LLC – 811 

• Johnson & Johnson – 799 

• Becton, Dickinson & Co – 687 

• Bayer AG – 653 

• PHC Holdings Corporation – 609 

• Alfred E. Mann Foundation For Scientific Research – 600 

Top Cited Patents (Forward Citations) 

• US6001067A – 1,579 

• US4757022A – 1,534 

• US20060016700A1 – 1,487 

• US20060015020A1 – 1,467 

• US6558321B1 – 1,455 

• US20030032874A1 – 1,443 

• US20060020192A1 – 1,394 

• US6931327B2 – 1,361 

• US6702857B2 – 1,351 

• US6741877B1 – 1,298 

Top Citing Patents (Backward Citations) 

• US11883164B2 – 3,215 

• US11051726B2 – 3,163 

• US12150250B2 – 3,141 

• US11943876B2 – 3,140 

• US11706876B2 – 3,133 

• US11000213B2 – 3,126 

• US10925524B2 – 3,124 

• US10898114B2 – 3,123 

• US10918318B2 – 3,123 

• US11350862B2 – 3,119 

Litigation Activities 

• Active Cases: 25 

• Inactive Cases: 87 

• Appeals: 21 

• Patents in Litigation: 57 

• Petitions: 33 

• Reexaminations: 68 

• Chinese PRBs: 5 

• Related Parties: 7 

Notable M&A (With Verified Figures) 

• TypeZero Technologies (2018) – DexCom acquired TypeZero Technologies to expand automated insulin delivery and closed-loop diabetes management capabilities. 

• SweetSpot Diabetes Care (2012) – Acquisition strengthened DexCom’s data management and analytics platform for diabetes care. 

Business Performance 

DexCom reported fiscal year 2024 revenue of approximately US$3.6 billion, driven primarily by global sales of its continuous glucose monitoring systems. The company operates across direct-to-consumer and healthcare provider channels, with revenue growth supported by expanded international adoption and next-generation CGM product launches. 

Leadership  

• Kevin Sayer – Chairman, President & Chief Executive Officer 

• Jereme Sylvain – Executive Vice President & Chief Financial Officer 

• Jake Leach – Executive Vice President & Chief Operating Officer 

Headquarters 

San Diego, California, United States